CD79A and COVID-19: Numerous studies demonstrated the early production of IgA and its presence in symptomatic and asymptomatic suspected COVID-19 patients, making IgA the ideal immunological biomarker to determine SARS-CoV-2 in the early stage and then apply adequate measures to isolate and treat the infected patients [89,91,92].